Journal List > Korean J Endocr Surg > v.3(2) > 1060206

TOOLS
Park and Clark: Troglitazone Increases the Susceptibility to TRAIL-Induced Apoptosis in Thyroid Cancer Cell Lines
Original Article

Korean Journal of Endocrine Surgery 2003; 3(2): 113-120.

Published online: 31 October 2003

DOI: https://doi.org/10.16956/kjes.2003.3.2.113

Troglitazone Increases the Susceptibility to TRAIL-Induced Apoptosis in Thyroid Cancer Cell Lines

Jin-Woo Park, M.D., Orlo H. Clark1

Department of Surgery, Chungbuk National University, Cheongju, Korea.

1Department of Surgery, University of California, San Francisco, UCSF/Mount Zion Medical Center, San Francisco, USA.

Correspondence: jwpark@med.chungbuk.ac.kr

      Accepted 18 September 2003

Copyright © 2003 Korean Association of Thyroid and Endocrine Surgeons; KATES

(open-access):

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induces apoptosis in many human cancer cells but not in normal cells. Thyroid cancer cells, however, appear to be relatively resistant to TRAIL-induced apoptosis. We investigated the effect of troglitazone, a PPARγ agonist, on TRAIL-induced apoptosis in thyroid cancer cells.

Methods

We used 6 thyroid cancer cell lines: TPC-1, FTC- 133, FTC-236, FTC-238, XTC-1, and ARO82-1. We used flow cytometry to detect apoptosis and used MTT assay to measure anti-proliferation effects. ANOVA was used for statistical analysis.

Results

TPC-1 cells were the most sensitive to soluble TRAIL. FTC-133 and ARO82-1 were resistant to TRAIL and growth inhibition was less than 20% at concentration of 800 ng/ml of TRAIL. In both TPC-1 (TRAIL-sensitive) and FTC- 133 (TRAIL-resistant) thyroid cancer cell lines, pretreatment with troglitazone enhanced TRAIL-induced cell death significantly. Bcl-family proteins did not seem to be involved in sensitization of TRAIL-induced apoptosis by troglitazone.

Conclusion

TRAIL in combination with troglitazone induces apoptosis in thyroid cancer cells at suboptimal concentrations that can not be achieved using TRAIL alone.

Keywords: TRAIL, Apoptosis, PPARγ, Thyroid cancer

TOOLS
Similar articles